Can hemochromatosis (iron overload disorder) cause secondary polycythemia (increased red blood cell mass)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hemochromatosis and Secondary Polycythemia

No, hemochromatosis does not cause secondary polycythemia—in fact, patients with hemochromatosis characteristically have elevated hemoglobin and hematocrit levels due to increased iron availability for erythropoiesis, which represents a distinct physiological mechanism from true secondary polycythemia. 1, 2

Understanding the Hematologic Profile in Hemochromatosis

Elevated Red Blood Cell Parameters Are Expected

  • Patients with hemochromatosis typically demonstrate increased hemoglobin levels, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) related to increased iron availability for erythropoiesis. 3

  • In a retrospective cohort of 213 hemochromatosis patients, the mean hemoglobin was 15.0 g/dL, with 27.6% meeting criteria for polycythemia, while only 10.8% had anemia despite multiple comorbidities that typically cause anemia in the general population. 1

  • Median hemoglobin and hematocrit values in C282Y homozygotes were 15.5 g/dL and 44.9% respectively, with similar or higher values in other HFE mutation patterns. 2

Mechanism: Iron Availability, Not Hypoxia

  • The elevated red blood cell parameters in hemochromatosis result from increased iron uptake by erythroid precursors in bone marrow due to increased availability of both transferrin-bound and non-transferrin-bound iron (NTBI), not from hypoxia-driven erythropoietin production. 2

  • This distinguishes hemochromatosis from true secondary polycythemia, which is defined as a physiological increase in red blood cell mass in response to hypoxemia or pathological erythropoietin production. 3

  • True secondary polycythemia causes include hypoxic processes (chronic lung disease, cardiac shunts, high altitude, sleep apnea), hemoglobinopathies with high oxygen affinity, and erythropoietin-producing tumors (renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma). 4

Critical Clinical Distinction

Anemia in Hemochromatosis Should Prompt Investigation

  • Anemia is NOT a characteristic feature of hemochromatosis—finding anemia in a patient with hemochromatosis should prompt thorough investigation for other unrelated causes. 3

  • In the cohort study, concurrent malignancy and chronic renal insufficiency were significantly associated with anemia (p < 0.001), but serum ferritin levels were not associated with anemia or polycythemia on multivariate analysis. 1

  • Patients with hemochromatosis maintained normal or elevated hemoglobin despite conditions typically associated with anemia (gastrointestinal bleeding, end-stage renal disease), suggesting a protective effect of iron overload. 2

Clinical Pitfall to Avoid

Do not confuse the elevated hemoglobin/hematocrit commonly seen in hemochromatosis with true secondary polycythemia requiring different management. 4 The elevated red cell parameters in hemochromatosis are a consequence of iron excess and resolve with phlebotomy therapy, whereas secondary polycythemia requires addressing the underlying hypoxic or erythropoietin-driven process. 3

In the study cohort, 67.1% of hemochromatosis patients received phlebotomy, and elevated hemoglobin levels persisted despite absence of established reasons for secondary polycythemia (only 21.7% were tobacco users and 8.6% had pulmonary diagnoses). 2

References

Research

Polycythemia in Patients With Hereditary Hemochromatosis: Real or Myth?

Journal of clinical medicine research, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Causes de la Polyglobulie

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.